Czech National Bank’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$39.1M Buy
1,622,280
+73,802
+5% +$1.93M 0.21% 83
2026
Q1
$43.5M Buy
1,548,478
+49,243
+3% +$1.31M 0.29% 64
2025
Q4
$37.3M Buy
1,499,235
+55,224
+4% +$1.39M 0.24% 78
2025
Q3
$36.8M Buy
1,444,011
+54,306
+4% +$1.34M 0.25% 76
2025
Q2
$33.7M Buy
1,389,705
+88,131
+7% +$2.06M 0.26% 74
2025
Q1
$33M Buy
1,301,574
+72,858
+6% +$1.91M 0.3% 64
2024
Q4
$32.6M Buy
1,228,716
+74,350
+6% +$2.02M 0.3% 59
2024
Q3
$33.4M Buy
1,154,366
+74,737
+7% +$2.18M 0.34% 56
2024
Q2
$30.2M Buy
1,079,629
+86,132
+9% +$2.37M 0.35% 52
2024
Q1
$27.6M Buy
993,497
+4,395
+0.4% +$122K 0.36% 53
2023
Q4
$28.5M Buy
989,102
+2,305
+0.2% +$69.7K 0.41% 44
2023
Q3
$32.7M Buy
986,797
+318,589
+48% +$11.3M 0.52% 34
2023
Q2
$24.5M Buy
668,208
+6,929
+1% +$270K 0.56% 30
2023
Q1
$27M Buy
661,279
+3,894
+0.6% +$168K 0.67% 25
2022
Q4
$33.7M Buy
657,385
+5,150
+0.8% +$247K 0.9% 19
2022
Q3
$28.5M Buy
+652,235
New +$31.7M 0.82% 19

Other funds holding PFE

Czech National Bank's PFE Position: Q2 2026 in Review

Czech National Bank increased its Pfizer (PFE) stake by 4.8% in Q2 2026, buying an estimated $1.93M and bringing the position to 1,622,280 shares worth $39.1M. The position accounts for 0.21% of the portfolio, ranked #83.

Czech National Bank first reported a position in PFE in Q3 2022 and has held it in 16 quarters since. The position peaked at $43.5M in Q1 2026. 1,090 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Czech National Bank held 1,622,280 shares of Pfizer worth $39.1M as of Q2 2026.
  • Czech National Bank bought 73,802 Pfizer shares in Q2 2026, an estimated $1.93M.
  • Pfizer made up 0.21% of Czech National Bank's portfolio in Q2 2026, its #83 holding.
  • Czech National Bank first reported a position in Pfizer in Q3 2022 and has held it in 16 quarters since.
  • Czech National Bank's Pfizer position peaked at $43.5M in Q1 2026.
  • 1,090 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Czech National Bank's 13F filing for Q2 2026, filed 8 Jul 2026.